Yahoo
NYSE - Nasdaq Real Time Price USD

Abbott Laboratories (ABT)

102.70 -0.40 (-0.39%)
As of 1:23:29 PM EDT. Market Open.
Trade ABT on Coinbase

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
Name Title Pay Exercised Year Born
Mr. Robert B. Ford
Executive Chairman & CEO 4.43M 26.48M 1974
Mr. Philip P. Boudreau
CFO & Executive VP of Finance 2.1M -- 1973
Mr. Daniel Gesua Sive Salvadori
Executive VP and Group President of Established Pharmaceuticals & Nutritional Products 1.52M 2.14M 1979
Mr. Christopher J. Scoggins
Executive Vice President of Diabetes Care 2.06M 8.59M 1970
Ms. Lisa D. Earnhardt
Executive VP & Group President of Medical Devices 2.39M 4.83M 1970
Ms. Sabina Ewing
Senior VP of Business & Technology Services and Chief Information Officer -- -- 1974
Mr. Michael Comilla
Vice President of Investor Relations. -- -- --
Erica L. Battaglia
VP and Chief Ethics & Compliance Officer -- -- --
Ms. Elizabeth C. Cushman
Executive VP, General Counsel & Secretary -- -- 1970
Ms. Melissa Brotz
Senior Vice President of Global Marketing & External Affairs -- -- --

Abbott Laboratories

100 Abbott Park Road
Abbott Park, IL 60064-6400
United States
224 667 6100 https://www.abbott.com
Sector: 
Healthcare
Industry: 
Medical Devices
Full Time Employees: 
122,000

Description

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.

Corporate Governance

Abbott Laboratories’s ISS Governance QualityScore as of October 1, 2026 is 5. The pillar scores are Audit: 9; Board: 6; Shareholder Rights: 2; Compensation: 6.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

October 21, 2026 at 12:30 PM UTC

Abbott Laboratories Earnings Date

November 16, 2026 at 12:00 AM UTC

Dividend Date

Recent Events

October 21, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

October 15, 2026 at 12:00 AM UTC

Ex-Dividend Date

August 20, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

July 28, 2026 at 12:00 AM UTC

10-Q: Periodic Financial Reports

July 16, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

June 18, 2026 at 12:00 AM UTC

11-K: Annual report of employee stock purchase

May 27, 2026 at 12:00 AM UTC

SD: Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)

April 29, 2026 at 12:00 AM UTC

10-Q: Periodic Financial Reports

April 27, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

April 24, 2026 at 12:00 AM UTC

S-8: Offering Registrations

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: